ReviewFamily medicine and community health2021
Rationales and uncertainties for aspirin use in COVID-19: a narrative review.
Review in Family medicine and community health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Effect of antiplatelet therapy after COVID-19 diagnosis: A systematic review with meta-analysis and trial sequential analysis.PloS one · 2024Pooled it
- Control of type 2 diabetes in patients with cancer and chronic pro-inflammatory cytokines during the COVID-19 pandemic.Journal of medicine and life · 2025Article
- Acetylsalicylic acid disrupts SARS-CoV-2 spike protein glycosylation and selectively impairs binding to ACE2.Frontiers in immunology · 2025Article
- Association between coronavirus 2 infection and preeclampsia among unvaccinated women.Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia · 2025Article
- Effect of Aspirin Use on the Adverse Outcomes in Patients Hospitalized for COVID-19.Cardiology research · 2024Article
- The 125th Anniversary of Aspirin-The Story Continues.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Acute thrombosis of the lower limb arteries on the background of the XBB.1.5 ("Kraken") subvariant of omicron SARS-COV-2 - medical or surgical treatment?Indian journal of thoracic and cardiovascular surgery · 2023Article
- Interrelationship between COVID-19 and Coagulopathy: Pathophysiological and Clinical Evidence.International journal of molecular sciences · 2023Review
- Follow-Up of a Cohort of Patients with Post-Acute COVID-19 Syndrome in a Belgian Family Practice.Viruses · 2022Article
- Evaluation of Low-Dose Aspirin use among Critically Ill Patients with COVID-19: A Multicenter Propensity Score Matched Study.Journal of intensive care medicine · 2022Article
- Aspirin use is associated with decreased inpatient mortality in patients with COVID-19: A meta-analysis.American heart journal plus : cardiology research and practice · 2022Article
- Effect of low dose acetylsalicylic acid and anticoagulant on clinical outcomes in COVID-19, analytical cross-sectional study.Health science reports · 2022Article
- A Comprehensive Overview of Globally Approved JAK Inhibitors.Pharmaceutics · 2022Review
- Aspirin and Infection: A Narrative Review.Biomedicines · 2022Review
- Antiplatelet therapy and outcome in COVID-19: the Health Outcome Predictive Evaluation Registry.Heart (British Cardiac Society) · 2022Observational
- Current Insights and Molecular Docking Studies of the Drugs under Clinical Trial as RdRp Inhibitors in COVID-19 Treatment.Current pharmaceutical design · 2022Article
- An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment.Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy · 2021Review
- Acetylsalicylic Acid Compared with Enoxaparin for the Prevention of Thrombosis and Mechanical Ventilation in COVID-19 Patients: A Retrospective Cohort Study.Clinical drug investigation · 2021Article
- Statins and Risk of Thrombosis in Critically ill Patients with COVID-19: A Multicenter Cohort Study.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisArticle
- SARS-CoV-2 gamma variant and chronic arterial insufficiency due to late arterial thrombosis.International journal of health sciencesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 6 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo review the pathophysiology of COVID-19 disease, potential aspirin targets on this pathogenesis and the potential role of aspirin in patients with COVID-19.
designNarrative review.
settingThe online databases PubMed, OVID Medline and Cochrane Library were searched using relevant headlines from 1 January 2016 to 1 January 2021. International guidelines from relevant societies, journals and forums were also assessed for relevance.
participantsNot applicable.
resultsA review of the selected literature revealed that clinical deterioration in COVID-19 is attributed to the interplay between endothelial dysfunction, coagulopathy and dysregulated inflammation. Aspirin has anti-inflammatory effects, antiplatelet aggregation, anticoagulant properties as well as pleiotropic effects on endothelial function. During the COVID-19 pandemic, low-dose aspirin is used effectively in secondary prevention of atherosclerotic cardiovascular disease, prevention of venous thromboembolism after total hip or knee replacement, prevention of pre-eclampsia and postdischarge treatment for multisystem inflammatory syndrome in children. Prehospital low-dose aspirin therapy may reduce the risk of intensive care unit admission and mechanical ventilation in hospitalised patients with COVID-19, whereas aspirin association with mortality is still debatable.
conclusionThe authors recommend a low-dose aspirin regimen for primary prevention of arterial thromboembolism in patients aged 40-70 years who are at high atherosclerotic cardiovascular disease risk, or an intermediate risk with a risk-enhancer and have a low risk of bleeding. Aspirin's protective roles in COVID-19 associated with acute lung injury, vascular thrombosis without previous cardiovascular disease and mortality need further randomised controlled trials to establish causal conclusions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.